Table 3.

Pulsatile insulin study: baseline17

A. Randomized trial of DCCT protocol (control) versus DCCT protocol 6 days/week + pulsatile insulin (infusion group)   1 day/week in type 1 diabetic patients with proteinuria, effect on progression of loss of renal function as measured by Ccreat Seventy-one patients seen every week Distribution: control (n = 34), infusion (n = 37) B. ACE inhibitors preferred for blood pressure control Forty-five patients Distribution: control (n = 25) infusion (n = 20) Distribution: no ACE inhibitors: control (n = 9) infusion (n = 17), P = ns C. Blood pressures (mmHg) by 24-h ambulatory method not significantly different at baseline, 52 weeks, and 78 weeks
Baseline	Infusion group (n = 37)	Control group (n = 34)	P value
Systolic	133.6 ± 3.2	132.5 ± 2.6	0.79
Diastolic	77.8 ± 1.5	79.6 ± 1.7	0.44
52 weeks	Infusion group (n = 37)	Control group (n = 34)	P value
Systolic	136.0 ± 2.7	133.2 ± 2.6	0.46
Diastolic	76.9 ± 1.8	78.7 ± 1.9	0.50
Baseline	Infusion group (n = 23)	Control group (n = 26)	P value
Systolic	134.8 ± 4.7	134.5 ± 3.1	0.96
Diastolic	78.3 ± 1.8	80.4 ± 2.1	0.46
78 weeks	Infusion group (n = 23)	Control group (n = 26)	P value
Systolic	131.6 ± 3.8	135.1 ± 3.4	0.49
Diastolic	74.7 ± 1.8	78.8 ± 2.2	0.17

Notes: Slopes of loss of Ccreat not significantly different at 52 weeks (n = 71); significantly different at 78 weeks (n = 49); did not change when the graph was drawn from 52 to 78 weeks.